HealthPolitics
STAT+: White House pulls nomination of Heidi Overton to lead FDA
Publication: STAT
Author: Margaret Manto and Daniel Payne
Source published: 18/11/2026, 00:44:05 UTC
Briefing created: 18/11/2026, 03:07:04 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 18/11/2026, 03:06:24 UTC.
Briefings
The Trump administration withdrew Heidi Overton's nomination to lead the FDA after the Senate Health Committee failed to secure sufficient Republican support. Despite the committee leader's claim that Overton had adequate backing, the White House officially abandoned the confirmation path. This event occurred on November 18, 2026, following the committee's expected vote on Wednesday.
Key points
- The Trump administration withdrew Heidi Overton's nomination to lead the FDA after the Senate Health Committee failed to secure sufficient Republican support.
- Senate Committee leader Sen. Bill Cassidy stated Overton had sufficient support to clear his committee, but the White House later abandoned the confirmation path.
Context
This is a confirmed event from the Trump administration regarding the FDA leadership nomination. The White House officially withdrew the nomination after the Senate Health Committee failed to secure sufficient Republican support, despite the committee leader's claim that Overton had adequate backing.
Limitations
Evidence is limited to a single source report from November 18, 2026, stating the White House withdrew the nomination. The source does not confirm the committee's final vote outcome or the specific reasons for the withdrawal beyond the committee leader's statement.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 18/11/2026, 03:07:04 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeifd5e5cr2sopkmaaftd3tsgwuwrq6l46z634qvltsjsl5dixvbzra